Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) Research & Development (2017 - 2025)

Neuroone Medical Technologies' Research & Development history spans 7 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Research & Development rose 24.16% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $5.1 million, up 10.28%, while the annual FY2025 figure was $5.0 million, 1.62% down from the prior year.
  • Research & Development reached $1.2 million in Q4 2025 per NMTC's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.9 million in Q2 2023 to a low of $901134.0 in Q2 2021.
  • Average Research & Development over 5 years is $1.3 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Research & Development: soared 54.36% in 2023, then crashed 37.41% in 2024.
  • A 5-year view of Research & Development shows it stood at $1.1 million in 2021, then surged by 47.44% to $1.6 million in 2022, then decreased by 5.13% to $1.5 million in 2023, then crashed by 32.44% to $1.0 million in 2024, then increased by 24.16% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Research & Development are $1.2 million (Q4 2025), $1.1 million (Q3 2025), and $1.2 million (Q2 2025).